What AVVA Pharmaceuticals does

AVVA Pharmaceuticals Ltd is a Cyprus-incorporated (Limassol) private pharmaceutical company that develops biological medicines and new small molecules targeting infectious and metabolic diseases. The company operates three business lines: (1) a branded product portfolio of five commercial pharmaceutical products — Ursoliv (hepatoprotector combining ursodeoxycholic acid and lactulose), Alcofiltrum (patented hangover dietary supplement), Lactofiltrum and Filtrum (first-in-class lignin-based products for eczema/atopic dermatitis and diarrhea management, respectively), and Micrazym (pancreatic enzymes for exocrine pancreatic insufficiency); (2) an R&D pipeline of five programs — recombinant Liraglutide API manufacturing technology (GLP-1 receptor agonist for diabetes/weight management) using a proprietary E. coli strain with patent-protected recombinant plasmid DNA and a fermentation cycle of approximately 8 hours versus roughly 5 days for the originator's S. cerevisiae process, an anti-IL-26 humanized monoclonal antibody for psoriasis (in collaboration with CHUV/University of Lausanne), a long-acting GLP1R agonist for neurodegenerative diseases, a dual-action acetylcholinesterase inhibitor (C29) for Alzheimer's disease, and an AGE inhibitor (two pyridoxine derivatives) for diabetic retinopathy; and (3) an API Trading Services division supplying over 40 generic APIs and excipients meeting GMP standards to pharmaceutical manufacturers.

The company generates revenue through product sales via a global distributor network spanning Europe, Africa, Asia, Americas, and Oceania (with named partners including Acino, Amneal, Alfasigma, Klinge, Unil, Abigo, Azure Pharmaceuticals, CMG, and Allgen), transaction-based API trading, and licensing/technology transfer (including a 15-year license/milestone/royalty structure offered for the Liraglutide manufacturing technology). Its core customer segments are metabolic and chronic disease patients, general healthcare consumers, and pharmaceutical manufacturers requiring API supply. AVVA holds a 2018 Eurostars grant (European Commission, Horizon 2020) for Lactomezole development, has achieved EU regulatory milestones including first-in-class lignin product submissions and third-worldwide Micrazym submission across 16 EU countries, and conducts distributed research with named principal investigators at premier institutions including the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Arbuzov Institute, Kazan Federal University, and CHUV. The company has 11-50 employees and operates without disclosed revenue, institutional investor backing, or parent company affiliation.

Name

AVVA Pharmaceuticals

Legal name

AVVA Pharmaceuticals Ltd

Website

https://avvapharma.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

AVVA Pharmaceuticals Ltd is a Cyprus-based private pharmaceutical company developing biological medicines and small molecules for metabolic and infectious diseases, with five commercial products (Ursoliv, Alcofiltrum, Lactofiltrum, Filtrum, Micrazym), five R&D programs including a proprietary Liraglutide API technology, and an API trading division serving global pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Biological medicines
• Small molecule drugs
• Active pharmaceutical ingredients
• Lignin-based therapeutics
• Recombinant protein production

Headquarters

HQ city

Limassol

HQ country

Cyprus

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs) Trading: AVVA Pharmaceuticals supplies active pharmaceutical ingredients and excipients from global API manufacturers. They assist clients throughout the whole purchasing process with GMP-compliant suppliers providing APIs with CTD DMF or COS documentation.
2. Product Sales: Sale of branded pharmaceutical products including Ursoliv (hepatoprotector), Alcofiltrum (hangover treatment), Lactofiltrum (eczema treatment), Filtrum (diarrhea management), and Micrazym (pancreatic enzymes).
3. Licensing and Technology Transfer: Licensing of developed API manufacturing technologies (e.g., Liraglutide technology) with license fees, milestone payments, and royalties for 15 years post commercialization.
4. Licensing Opportunities: Partnership and licensing opportunities for pharmaceutical development programs including novel drug candidates and formulations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

AVVA Pharmaceuticals develops, manufactures, and commercializes biological medicines and small molecules for infectious and metabolic diseases, including hepatoprotectors (Ursoliv), hangover dietary supplements (Alcofiltrum), eczema/atopic dermatitis treatments (Lactofiltrum), anti-diarrheal lignin-based products (Filtrum), and pancreatic enzyme replacements (Micrazym). The company also trades over 40 GMP-compliant active pharmaceutical ingredients and excipients sourced from global manufacturers, and licenses proprietary recombinant manufacturing technology (notably for Liraglutide API) through a global partnership network spanning Europe, Africa, Asia, the Americas, and Oceania.

Product overview

AVVA Pharmaceuticals Ltd is a European pharmaceutical company offering a portfolio of commercial pharmaceutical products and active pharmaceutical ingredients. Their commercial products include Ursoliv (hepatoprotector), Alcofiltrum (hangover dietary supplement), Lactofiltrum (atopic dermatitis/eczema treatment), Filtrum (diarrhea management), and Micrazym (pancreatic enzymes). Their R&D pipeline includes Liraglutide (diabetes API technology), IL-26 AB monoclonal antibody (psoriasis), GLP1R Agonist (neurodegenerative diseases), Dual AChE Inhibitor (Alzheimer's), and AGE DRP (diabetic retinopathy). Through their Trading Services division, they supply over 40 generic APIs including antibiotics, cardiovascular drugs, and gastrointestinal medications, all meeting GMP requirements.

Differentiator

Problem solved

Functional benefit

Brands

• Ursoliv: Hepatoprotector combining ursodeoxycholic acid and lactulose
• Alcofiltrum
• Lactofiltrum
• Filtrum
• Micrazym

Products and services

• Ursoliv Hepatoprotector combining ursodeoxycholic acid and lactulose, delivering hepatoprotective, cholagogic, cholelitholitic, lipid-lowering, and prebiotic effects for patients with liver conditions.
• Alcofiltrum Patented dietary supplement clinically tested to alleviate hangover symptoms through sorption of fusel alcohols, containing Mixed Plant Cell Wall Fibers, glycine, dihydromyricetin, and Vitamin B1.
• Lactofiltrum Combination of Mixed Plant Cell Wall Fibers and lactitol for managing eczema and atopic dermatitis through the gut-skin axis, clinically tested in 15 trials.
• Filtrum Non-systemic diarrhea management product containing lignin, a polymer of plant origin with high sorption capacity for pathogens and toxins.
• Micrazym Pancreatic enzymes in micro-granule form with acid protective layer for treating exocrine pancreatic insufficiency.
• Active Pharmaceutical Ingredients (APIs) and Excipients Trading Over 40 active pharmaceutical ingredients and excipients supplied from global API manufacturers, including Azithromycin, Amoxicillin, Atorvastatin, Ciprofloxacin, Esomeprazole, Pancrelipase, and others, all meeting GMP requirements with CTD DMF or COS documentation.
• Liraglutide API Technology (Recombinant Manufacturing Technology) Recombinant Liraglutide API manufacturing technology (GLP-1 receptor agonist) for type 2 diabetes and weight management, developed with E. coli strain technology offering advantages over originator's S. cerevisiae process.
• Anti-IL-26 Monoclonal Antibody (IL-26 AB) Humanized monoclonal antibody targeting IL-26 for psoriasis treatment, with preclinical proof-of-concept demonstrated in animal models.
• GLP1R Agonist (Neurodegenerative Programme) Long-acting GLP-1 receptor agonist with high blood-brain barrier permeability for treatment of neurodegenerative diseases including Alzheimer's and Parkinson's.
• Dual AChE Inhibitor (C29) Novel small molecule (C29) dual-action AChE inhibitor that also prevents beta-amyloid aggregation for Alzheimer's disease treatment.
• AGE DRP Inhibitor (Diabetic Retinopathy Programme) Novel inhibitor of advanced glycation end-products (2 pyridoxine derivative molecules) for prevention of diabetic retinopathy.

Quantifiable outcome

• Lignin is 1000 times more effective than charcoal in neutralizing pathogenic bacteria
• +6 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

19 partnerships are on record, tiered core and major.

• Azure PharmaceuticalscoreStrategic or Co-development PartnerPharmaceutical partner shown in AVVA's global partner network. Azure Pharmaceuticals collaborates in pharmaceutical development and operations.
• CMGcoreStrategic or Co-development PartnerPartner in AVVA's pharmaceutical sector partnerships with expertise in pharmaceutical development, strategy, analysis and operations.
• AllgencoreStrategic or Co-development PartnerPharmaceutical development partner in AVVA's global network across Europe, Africa, Asia, Americas and Oceania.
• AcinocoreChannel Partner/ Reseller/ DistributorPharmaceutical company partner engaged in distribution and commercialization of pharmaceutical products.
• AmnealcoreChannel Partner/ Reseller/ DistributorPharmaceutical manufacturer and distributor partner in AVVA's global partner network.
• BioinnovacoreStrategic or Co-development PartnerInnovation-focused pharmaceutical partner in AVVA's network for pharmaceutical development and operations.
• UnilcoreChannel Partner/ Reseller/ DistributorPharmaceutical partner engaged in distribution activities within AVVA's global partnership network.
• CHUV (Centre Hospitalier Universitaire Vaudois)majorStrategic or Co-development PartnerUniversity hospital partner providing research expertise. CHUV's Department of Dermatology collaborates with AVVA on IL-26 antibody research for psoriasis through Prof. Michel Gilliet.
• AbexcoreChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner in AVVA's global network.
• AbigocoreChannel Partner/ Reseller/ DistributorPharmaceutical company partner in AVVA's partner network for product distribution.
• AspirecoreChannel Partner/ Reseller/ DistributorPharmaceutical partner engaged in distribution of AVVA's products.
• TasoscoreChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner in AVVA's network.
• VelitcoreChannel Partner/ Reseller/ DistributorPharmaceutical partner in AVVA's global distribution network.
• KlingecoreChannel Partner/ Reseller/ DistributorPharmaceutical company partner for product distribution.
• AlfasigmacoreChannel Partner/ Reseller/ DistributorItalian pharmaceutical company partner in AVVA's distribution network.
• Shemyakin and Ovchinnikov Institute of Bioorganic ChemistrymajorStrategic or Co-development PartnerResearch partnership for Liraglutide API technology development and GLP1R agonist research. Located in Russia, providing expertise in biomolecular modeling, bioorganic chemistry, and biotech production. Prof. Roman G. Efremov serves as Deputy scientific director and leads research efforts.
• Kazan Federal University - Research Center of PharmacymajorStrategic or Co-development PartnerResearch collaboration on AGE DRP inhibitor development. Inventors include Yuriy G. Shtyrlin (PhD, Doctor of Science, Director), Alexey D. Strelnik (PhD, Senior Researcher), Marya N. Agaphonova (PhD), and Oksana V. Bondar (PhD).
• Arbuzov Institute of Organic and Physical Chemistry of FRC Kazan Scientific Center of RASmajorStrategic or Co-development PartnerResearch partnership for Dual AChE Inhibitor (C29) development for Alzheimer's disease. Konstantin A. Petrov (PhD) leads the International Research and Innovation Center for Neurochemistry and Pharmacology. Vyacheslav E. Semenov (PhD, D.Sc.) heads the Laboratory of Chemistry of Nucleotide Bases.
• CHUV University Hospital and University of LausannemajorStrategic or Co-development PartnerCollaboration on anti-IL-26 antibody development for psoriasis. Prof. Michel Gilliet (MD) leads Immuno-dermatology Research at the Department of Dermatology. Jeremy Di Domizio (PhD) serves as Senior Scientist and Research Lab Supervisor.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Krka: Slovenian specialty/generics pharma with own API manufacturing, presence in CEE/CIS/EU markets, and pipeline across metabolic, gastroenterology, and CNS — similar business model mix to AVVA with branded generics, APIs, and emerging R&D.
• Alvotech: Specialty biopharmaceutical company focused on biosimilars including a Liraglutide biosimilar candidate, with proprietary recombinant manufacturing platforms — directly comparable to AVVA's biosimilar Liraglutide positioning and recombinant protein technology focus.
• Stada Arzneimittel: European-headquartered specialty and generics pharmaceutical company with a broad portfolio across multiple therapeutic areas and strong distribution across CIS/EU markets — closely comparable to AVVA's European specialty pharma + API trading + regional distribution model.
• Gedeon Richter: Hungarian specialty pharma with branded generics, API manufacturing, and CNS pipeline — comparable to AVVA's branded specialty products (Ursoliv, Lactofiltrum), API trading business, and CNS R&D (Dual AChE inhibitor).
• Polpharma: Polish generics and specialty pharma with API manufacturing and CIS/EU distribution — comparable regional specialty-pharma + API model with similar geographic footprint to AVVA.
• Alfasigma: Italian specialty pharma with strong gastroenterology and hepatology portfolio (including ursodeoxycholic acid products competing with Ursoliv) and pan-European distribution — directly comparable as both a peer and an AVVA distribution partner.
• Amneal Pharmaceuticals: US-headquartered specialty and generics pharma with global distribution, biosimilars pipeline, and growing presence across metabolic, CNS, and GI categories — comparable as both an AVVA distribution partner and a similar portfolio pharma with specialty/generics + biosimilars mix.
• Helsinn Healthcare: Private Swiss specialty pharma focused on oncology, gastroenterology, and supportive care with licensing-driven business model — comparable small-headcount, licensing-centric specialty pharma with EU/global distribution partners.

Broad incumbents

• Teva Pharmaceutical Industries: Global generics and specialty pharma leader with broad portfolio including CNS, gastroenterology, and biosimilars — comparable as a broader incumbent competing in many of AVVA's therapeutic categories.
• Novo Nordisk: Originator of Liraglutide and global GLP-1 leader with $6B+ Liraglutide franchise; AVVA's proprietary E. coli process directly competes against Novo Nordisk's S. cerevisiae manufacturing — making it the key reference competitor for AVVA's most differentiated technology asset.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AVVA Pharmaceuticals